Treatment of autoimmune disease by modulating annexin-1 (lipocortin 1)
The present invention provides a specific binding molecule which binds to Annexin-1 (Anx-A1) for use in the treatment of T cell-mediated disease.
1. A method of treating a T cell-mediated disease in a human comprising systemically administering to the human in need thereof a therapeutically effective amount of an antibody, or fragment thereof, that binds to Annexin-1 (Anx-A1), wherein the T cell-mediated disease is rheumatoid arthritis or multiple sclerosis, and wherein the antibody, or fragment thereof, ameliorates, eliminates or prevents one or more symptoms of the T cell-mediated disease.
2. The method of claim 1 wherein the antibody binds to an N-terminal peptide of Anx-A1 of at least 50 amino acid residues.
3. The method of claim 1 wherein the antibody binds to SEQ ID NO:1.
4. The method of claim 1 wherein the antibody binds to a fragment of at least 6 amino acids of SEQ ID NO:1.
5. The method of claim 1 wherein the antibody is a monoclonal antibody.
6. The method of claim 1 wherein the antibody fragment is chosen from Fab fragment, F(ab′) 2 fragment, Fv fragment, and single chain Fv (scFv) molecule.
7. The method of claim 1 wherein the antibody is a chimeric antibody.
8. The method of claim 1 wherein the antibody is a humanized antibody.
9. The method of claim 1 wherein the T cell-mediated disease is rheumatoid arthritis.
10. The method of claim 1 wherein the T cell-mediated disease is multiple sclerosis.